Celticare

Celtis Therapeutics, originally founded as Celticare in 2018, is a South Korean biotechnology company dedicated to developing novel small molecule drugs for fibrosis and oncology. The company's primary focus is on the TGF-beta signaling pathway, which plays a critical role in tissue scarring and tumor immune evasion. Its lead candidate, CT-01, is a potent and selective inhibitor of the Transforming growth factor-beta receptor type 1 (ALK5), currently in early-stage clinical development for indications such as non-alcoholic steatohepatitis (NASH) and liver fibrosis. Celtis is also exploring the potential of its pipeline in oncology, aiming to combine its TGF-beta inhibitors with checkpoint inhibitors to improve outcomes in solid tumors. The company is headquartered in Seoul and is backed by several prominent Korean venture capital firms.